Boston

Running trials

• Active, not recruiting

  Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

  NCT02609776· Phase 1· Source

• Active, not recruiting

  An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

  NCT02531516· Phase 3· Source

• Active, not recruiting

  A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

  NCT01946204· Phase 3· Source

• Active, not recruiting

  A Long-term Extension Study of PCI-32765 (Ibrutinib)

  NCT01804686· Phase 3· Source

• Recruiting

  Product Surveillance Registry

  NCT01524276· Source

• Active, not recruiting

  Psoriasis Longitudinal Assessment and Registry

  NCT00508547· Source

• Active, not recruiting

  A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

  NCT00606346· Source

• Recruiting

  Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

  NCT00271180· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease1 recruiting
• Heart failure1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Actis Total Hip System 2 Year Follow-up

  NCT02783274· Source

• Completed

  A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

  NCT02316106· Phase 2· Source

• Completed

  Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

  NCT02252172· Phase 3· Source

• Completed

  Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer

  NCT02141438· Source

• Completed

  Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

  NCT02136134· Phase 3· Source

• Completed

  A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

  NCT02076009· Phase 3· Source

• Completed

  Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

  NCT02043678· Phase 3· Source

• Completed

  Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

  NCT02073994· Phase 1· Source

• Completed

  A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

  NCT01998971· Phase 1· Source

• Completed

  Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate

  NCT01792687· Phase 1· Source

• Completed

  A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

  NCT01712490· Phase 3· Source

• Completed

  Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

  NCT01615029· Phase 1/2· Source

• Completed

  IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

  NCT01314118· Phase 2· Source

• Completed

  Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

  NCT01171898· Phase 1/2· Source

• Terminated

  A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

  NCT01065454· Phase 2· Source